Inflammatory Bowel Disease

Patients treated with biologic therapy for inflammatory diseases may not have a higher risk for developing melanoma, a systematic review and meta-analysis found.

Patients with late-onset inflammatory bowel disease had a greater recurrence of colorectal cancer than patients with early-onset, despite a shorter disease duration and strictly following recommended endoscopic surveillance guidelines, according to data from Digestive Disease Week.

Clinical hypnosis that includes focused relaxation and therapeutic suggestion may be a promising complementary therapy for children with Crohn’s disease, according to research from Digestive Disease Week.

No correlation was seen between dietary gluten intake and the risk for incidence Crohn’s disease or ulcerative colitis among women without celiac disease, according to data from Digestive Disease Week.

New data from the SECURE-IBD registry suggest that steroids — not anti-TNF therapy — increase the risk for severe COVID-19 among patients with inflammatory bowel disease. It was the top story in gastroenterology last week.

Pain scores in patients with inflammatory bowel disease did not improve during hospitalization despite high opioid use, according to research published in Digestive Disease and Sciences.

Approximately one-third of patients who underwent either a biologic dose change or discontinuation did not undergo objective disease activity assessment or therapeutic drug monitoring before therapy was altered, according to data from Digestive Disease Week.

Cholecystectomy in patients with Crohn’s disease was associated with markers of disease activity and worse quality of life in a multi-year study, according to research from Digestive Disease Week.

Treatment with Stelara was associated with superior outcomes in patients with Crohn’s disease who previously failed anti-TNF therapy, according to study results.

Research from Digestive Disease Week dominated the top stories in gastroenterology last week. One study showed that a ready-to-drink solution of sodium picosulfate, magnesium oxide and citric acid was an effective bowel preparation for patients with normal and impaired renal function undergoing a non-emergent colonoscopy.